Panacea Biotec Declines 4.96% Amid Mixed Signals and Elevated Valuation Risks
2026-11-21 16:07:10Key Events This Week 16 Nov: Intraday high surge of 7.69% to Rs.380.45 amid gap-up opening 16 Nov: Mixed quarterly results reveal strong revenue but negative cash flow 17 Nov: Valuation metrics signal elevated price risk with P/E ratio at 206.6 20 Nov: Sharp 4.83% drop to Rs.336.25 despite Sensex gains Week OpenRs.353.80 We...
Read More
Panacea Biotec Ltd is Rated Strong Sell
2026-11-21 10:10:19Panacea Biotec Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 24 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 November 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Panacea Biotec Ltd Valuation Shifts Signal Elevated Price Risk Amid Sector Comparisons
2026-11-17 08:01:08Panacea Biotec Ltd’s valuation metrics have undergone a marked deterioration, with its price-to-earnings (P/E) ratio soaring to 206.6 and price-to-book value (P/BV) rising to 2.58, signalling a shift from risky to very expensive territory. This valuation expansion contrasts sharply with both its historical averages and peer group benchmarks, raising concerns about price attractiveness amid subdued financial performance and negative returns over recent periods.
Read More
Panacea Biotec Ltd Reports Mixed Quarterly Results Amid Flat Financial Trend
2026-11-16 14:00:32Panacea Biotec Ltd’s latest quarterly results reveal a complex financial picture, with robust revenue growth and margin expansion contrasting sharply against deteriorating cash flow metrics. Despite a strong uptick in net sales and profitability for the quarter ended September 2026, the company’s overall financial trend has shifted from very positive to flat, prompting a downgrade in its Mojo Grade to Strong Sell.
Read More
Panacea Biotec Ltd Faces Bearish Momentum Amid Technical Downturn
2026-11-16 08:02:22Panacea Biotec Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen a marked shift in its technical momentum, with key indicators signalling a bearish trend. The company’s stock price has declined by 1.83% today, closing at ₹353.80, reflecting growing investor caution amid weakening technical signals and a downgrade in its Mojo Grade to Strong Sell.
Read More
Panacea Biotec Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-11-13 08:03:11Panacea Biotec Ltd has experienced a subtle shift in its technical momentum, moving from a bearish to a mildly bearish trend, reflecting a complex interplay of technical indicators. Despite a modest day gain of 1.65%, the stock’s broader technical signals and relative performance against the Sensex suggest cautious investor sentiment amid ongoing volatility in the Pharmaceuticals & Biotechnology sector.
Read More
Panacea Biotec Ltd is Rated Strong Sell
2026-11-10 10:10:16Panacea Biotec Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 24 August 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are based on the company’s current position as of 10 November 2026, providing investors with the latest insights into its performance and prospects.
Read More
Panacea Biotec Ltd is Rated Strong Sell
2026-10-16 10:10:25Panacea Biotec Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 24 August 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 16 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Panacea Biotec Ltd is Rated Strong Sell
2026-10-05 10:10:19Panacea Biotec Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 24 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
16-Nov-2026 | Source : BSEPlease find attached newspaper copies of the extract of statement of Unaudited Financial Results for the quarter and half year ended September 30 2026.
Board Meeting Outcome for Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half-Year Ended September 30 2026
14-Nov-2026 | Source : BSEWe would like to inform you that the Board of Directors has at its meeting held today i.e. Saturday November 14 2026 inter-alia considered and approved the Standalone and Consolidated Unaudited Financial Results of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and half-year ended September 30 2026.
Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half-Year Ended September 30 2026
14-Nov-2026 | Source : BSEPlease find attached Unaudited Financial Results for quarter and half year ended September 30 2026
Corporate Actions
No Upcoming Board Meetings
Panacea Biotec Ltd has declared 75% dividend, ex-date: 19 Sep 11
No Splits history available
No Bonus history available
No Rights history available